José López-Menéndez1, Javier Miguelena2, Carlos Morales3, Francisco Callejo3, Jacobo Silva3. 1. Cardiac Surgery, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, Km 9.7, Madrid 28034, Spain. 2. Cardiac Surgery, Hospital Universitario Ramón y Cajal, Madrid, Spain. 3. Cardiac Surgery, Hospital Universitario Central de Asturias, Oviedo, Spain.
Abstract
BACKGROUND: We analyzed the adequacy of the myocardial protection achieved with a single dose of retrograde crystalloid Celsior®, compared with an accepted standard (microplegia), in on-pump coronary artery bypass grafting surgery (CABG). METHODS: This was a retrospective comparative clinical study conducted in a single institution that included all the patients operated on who had elective isolated on-pump CABG, from March 2006 to June 2014. We evaluated maximum postoperative troponin T (TnT) as a marker of myocardial damage, adjusted for possible confounders using propensity score matching. We also analyzed markers of recovery of myocardial function, and the safety of the intravenous use of Celsior®. RESULTS: During the study period, 261 patients were included, divided in two groups: (a) continuous retrograde blood-based microplegia (114 patients); (b) retrograde single-dose crystalloid Celsior® (147 patients). The propensity score adjusted maximum TnT was significantly lower in the Celsior group [average treatment effect = -0.55 ng/dl; 95% confidence interval (CI) -1.10 to -0.1 ng/dl; p = 0.048]. There were no differences in the postoperative use of intra-aortic balloon of counterpulsation or in the requirements of high-dose inotropic medications. In-hospital mortality was equivalent in both study groups ( p = 0.73); surgical re-exploration because of bleeding was equivalent ( p = 0.37). There were no differences in prolonged mechanical ventilation ( p = 0.65) and intensive care unit length of stay ( p = 0.87). CONCLUSION: An isolated single dose of retrograde Celsior® may be an effective and safe myocardial protection strategy in on-pump CABG.
BACKGROUND: We analyzed the adequacy of the myocardial protection achieved with a single dose of retrograde crystalloid Celsior®, compared with an accepted standard (microplegia), in on-pump coronary artery bypass grafting surgery (CABG). METHODS: This was a retrospective comparative clinical study conducted in a single institution that included all the patients operated on who had elective isolated on-pump CABG, from March 2006 to June 2014. We evaluated maximum postoperative troponin T (TnT) as a marker of myocardial damage, adjusted for possible confounders using propensity score matching. We also analyzed markers of recovery of myocardial function, and the safety of the intravenous use of Celsior®. RESULTS: During the study period, 261 patients were included, divided in two groups: (a) continuous retrograde blood-based microplegia (114 patients); (b) retrograde single-dose crystalloid Celsior® (147 patients). The propensity score adjusted maximum TnT was significantly lower in the Celsior group [average treatment effect = -0.55 ng/dl; 95% confidence interval (CI) -1.10 to -0.1 ng/dl; p = 0.048]. There were no differences in the postoperative use of intra-aortic balloon of counterpulsation or in the requirements of high-dose inotropic medications. In-hospital mortality was equivalent in both study groups ( p = 0.73); surgical re-exploration because of bleeding was equivalent ( p = 0.37). There were no differences in prolonged mechanical ventilation ( p = 0.65) and intensive care unit length of stay ( p = 0.87). CONCLUSION: An isolated single dose of retrograde Celsior® may be an effective and safe myocardial protection strategy in on-pump CABG.
Authors: Jose López-Menéndez; Javier Miguelena; Carlos Morales; Carmen L Díaz; Francisco Callejo; Juan Carlos Llosa; Jacobo Silva Journal: Ann Thorac Surg Date: 2016-11-22 Impact factor: 4.330
Authors: Tomasz Timek; Charles Willekes; Olivia Hulme; Ben Himelhoch; Daniel Nadeau; Andrew Borgman; Jeff Clousing; Dick Kanten; Joe Wagner Journal: Ann Thorac Surg Date: 2016-03-24 Impact factor: 4.330
Authors: J D Vega; J L Ochsner; V Jeevanandam; D C McGiffin; K R McCurry; R M Mentzer; J C Stringham; R N Pierson; O H Frazier; A H Menkis; E D Staples; D L Modry; R W Emery; W Piccione; M Carrier; P J Hendry; S Aziz; S Furukawa; S M Pham Journal: Ann Thorac Surg Date: 2001-05 Impact factor: 4.330
Authors: P Giordano; G Scrascia; D D'Agostino; F Mastro; C Rotunno; M Conte; R Rociola; D Paparella Journal: Perfusion Date: 2013-05-13 Impact factor: 1.972
Authors: Gladdy George; A V Varsha; Madhu A Philip; Reshma Vithayathil; Dharini Srinivasan; Fx Sneha Princy; Raj Sahajanandan Journal: Ann Card Anaesth Date: 2022 Jul-Sep